Vanguard Capital Management
DTIL icon

Vanguard Capital Management’s Precision BioSciences DTIL Stock Holding History

Vanguard Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.77M Buy
1,116,241
+205,501
+23% +$1.45M ﹤0.01% 2901
2026
Q1 		$5.01M Buy
+910,740
New +$4.2M ﹤0.01% 3059

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's DTIL Position: Q2 2026 in Review

Vanguard Capital Management increased its Precision BioSciences (DTIL) stake by 23% in Q2 2026, buying an estimated $1.45M and bringing the position to 1,116,241 shares worth $8.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2901.

Vanguard Capital Management first reported a position in DTIL in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Vanguard Capital Management held 1,116,241 shares of Precision BioSciences worth $8.77M as of Q2 2026.
  • Vanguard Capital Management bought 205,501 Precision BioSciences shares in Q2 2026, an estimated $1.45M.
  • Precision BioSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2901 holding.
  • Vanguard Capital Management first reported a position in Precision BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.